CK Life Sciences Int'l., (Holdings) Inc. Stock price

Equities

775

KYG2176J1058

Food Processing

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
0.335 HKD -2.90% Intraday chart for CK Life Sciences Int'l., (Holdings) Inc. -16.25% -45.97%
Sales 2021 5.4B 690M Sales 2022 5.28B 674M Capitalization 7.59B 970M
Net income 2021 163M 20.83M Net income 2022 132M 16.87M EV / Sales 2021 2.3 x
Net Debt 2021 5.31B 679M Net Debt 2022 5.24B 670M EV / Sales 2022 2.43 x
P/E ratio 2021
43.8 x
P/E ratio 2022
57.5 x
Employees 1,932
Yield 2021
1.35%
Yield 2022
1.01%
Free-Float 25.02%
More Fundamentals * Assessed data
Dynamic Chart
CK Life Sciences Int'l., Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
XtalPi and CK Life Sciences Ink Agreement to Develop Cancer Molecular Diagnostic Models Using AI and Biomarker Data CI
CK Life Sciences to Present Preclinical Study of Cancer Vaccines at US Immunotherapy Conference MT
Ck Life Sciences Int'l., Inc. Announces Preclinical Data for Its Investigational Dual-Antigen Cancer Vaccines, Co-Targeting Prame and PD-L1 CI
CK Life Sciences International's Profit Slumps 43% in H1; Shares Down 3% MT
CK Life Sciences Int'l., Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
CK Life Sciences Int'l., Inc. Announces Ordinary Final Dividend for the Year Ended 31 December 2022, Payment Date 05 June 2023 CI
CK Life Sciences Int'l., Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
XtalPi Inc. and CK Life Sciences to Collaborate in Ai-Empowered Tumour Vaccine Research and Development, Opening A New Paradigm for Scientific Innovation CI
CK Life Sciences Int'l., Inc. Announces Retirement of Independent Non-Executive Director and Change in Composition of the Remuneration Committee CI
CK Life Sciences' H1 Profit Down 35% MT
CK Life Sciences Int'l., Inc. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
CK Life Sciences Investors Acquire Stake in Pharus for $5.5 Million Each MT
CK Life Sciences Int'l., Inc. Announces Ordinary Final Cash Dividend for the Year Ended 31 December 2021, Payable on 01 June 2022 CI
CK Life Sciences Int'l., Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day-2.90%
1 week-16.25%
Current month-29.47%
1 month-33.00%
3 months-45.97%
6 months-51.45%
Current year-45.97%
More quotes
1 week
0.34
Extreme 0.335
0.40
1 month
0.34
Extreme 0.335
0.54
Current year
0.34
Extreme 0.335
0.62
1 year
0.34
Extreme 0.335
0.82
3 years
0.34
Extreme 0.335
1.28
5 years
0.34
Extreme 0.335
1.34
10 years
0.34
Extreme 0.335
1.34
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 02-05-31
Director of Finance/CFO 64 05-09-30
President 78 02-05-31
Members of the board TitleAgeSince
Director/Board Member 82 02-05-31
Chairman 60 02-03-31
President 78 02-05-31
More insiders
Date Price Change Volume
24-03-28 0.335 -2.90% 6 216 000
24-03-27 0.345 -4.17% 4,906,000
24-03-26 0.36 -2.70% 5,242,000
24-03-25 0.37 -3.90% 3,346,000
24-03-22 0.385 -3.75% 4,850,323

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
CK Life Sciences Intl (Holdings) Inc is an investment holding company principally engaged in the development and sales of healthcare products. The Company operates through two segments. The Health segment is engaged in the development, production, marketing and sales of healthcare and pharmaceutical products. The healthcare brands under the Company include Lipa, Vitaquest and Sante Naturelle, among others. Its pharmaceutical products include cancer-related pharmaceuticals and painkillers, among others. The Agriculture-related Businesses segment is engaged in the operation of vineyards, as well as the development, production, marketing and sales of agriculture and related products. Its agricultural products include fertilizers and crop protection products, among others.
More about the company
  1. Stock
  2. Equities
  3. Stock CK Life Sciences Int'l., (Holdings) Inc. - Hong Kong S.E.